Synthetic genes encoding the human a-and /3-globin polypeptides have been expressed from a single operon in Escherichia coli. The a-and fi-globin polypeptides associate into soluble tetramers, incorporate heme, and accumulate to >5% of the total cellular protein. Purified recombinant hemoglobin has the correct stoichiometry of a-and (3-globin chains and contains a full complement of heme. Each globin chain also contains an additional methionine as an extension to the amino terminus. The recombinant hemoglobin has a C4 reversed-phase HPLC profile essentially identical to that of human hemoglobin AO and comigrates with hemoglobin AO on SDS/PAGE. The visible spectrum and oxygen affinity are similar to that of native human hemoglobin AO. The recombinant protein shows a reduction in Bohr and phosphate effects, which may be attributed to the presence of methionine at the amino termini of the a and (3 chains. We have also expressed the a-and (3-globin genes separately and found that the expression of the a-globin gene alone results in a marked decrease in the accumulation of a-globin in the cell. Separate expression of the (8-globin gene results in high levels ofinsoluble j3-globin. These observations suggest that the presence of aand (3-globin in the same cell stabilizes a-globin and aids the correct folding of (8-globin. This system provides a simple method for expressing large quantities of recombinant hemoglobin and allows facile manipulation of the genes encoding hemoglobin to produce functionally altered forms of this protein.
The prevalence ofinfectious agents in human blood products, such as red blood cells, has changed modern transfusion practice. This fact, and the need for an oxygen-carrying solution that can be administered quickly to patients requiring acute blood transfusion, has led to a continued interest in developing red-cell substitutes. The primary functional requirement of such substitutes is that they not only provide blood volume but also adequately deliver oxygen to the tissues. The use of cell-free solutions of hemoglobin (Hb) as a potential oxygen-carrying red-cell substitute has been investigated for decades (1) . Purified Hb has seen shown to efficiently transport oxygen in animals without appreciable toxicity (2) . The use of unmodified human Hb purified from red blood cells suffers from four limitations. (i) Hb purified from red blood cells loses a cofactor [2,3- bis(phospho)glycerate] resulting in an increase in the oxygen affinity. (ii) The dissociation of Hb tetramers into dimers leads to the rapid clearance of Hb from the circulatory system, resulting in a short circulating half-life and possibly renal toxicity (3) . (iii) Hb solutions derived from red cells may be contaminated with infectious agents. While sterilization of red blood cellderived Hb may be possible, it is often difficult to achieve M. ROEHRICH, PAUL E. COZART, STEVEN L. DURFEE, without compromising the functionality of the protein. (iv) The source of Hb from outdated units of human red blood cells is susceptible to supply limitation. The first two problems have been addressed by chemical modifications of Hb that alter its oxygen delivery characteristics and circulating half-life (4) . Alternatively, recombinant Hb could be modified by the techniques of protein engineering to modulate oxygen affinity and stabilize the protein from dissociation, thus avoiding problems attributable to chemical modification of Hb. In addition, production of Hb by fermentation could ensure a consistent supply of a protein free of blood-borne pathogens. For these reasons, we have developed a system that allows high-level production of human Hb in Escherichia coli.
Production of totally recombinant Hb presents a challenge in that it requires correct assembly of two nonidentical a and /3 subunits, followed by introduction of a reduced heme cofactor. A method for the production and engineering of semisynthetic human Hb in E. coli was described by Nagai et al. (5) . This method involved the synthesis of 83-globin fusion proteins with a cleavable linker sequence. The fusion protein was purified, cleaved to release the globin chain, and refolded in vitro in the presence of native a-globin and heme to gain a fully functional tetramer. We have developed an E. coli expression system that results in the expression of both globin chains. The a-and P-globin chains fold in vivo and incorporate endogenous heme, with recombinant Hb accumulating in the soluble cytoplasmic fraction of the cell.
MATERIALS AND METHODS
Construction of a Synthetic Hb Operon. Synthetic oligodeoxynucleotides were synthesized using a Biosearch model 8600 synthesizer. Codons were chosen based on the E. coli codon bias (6) . In some cases the choice of codons was dictated by the need to include convenient restriction sites. Oligonucleotides were purified by preparative polyacrylamide gel electrophoresis in 20% acrylamide gels containing 7 M urea in 1 x TBE (90 mM Tris borate, pH 8.3/2 mM Na2EDTA). Regions of the gel containing the full-length oligonucleotide were excised and incubated in 0.1 M Tris RCl, pH 7.8/0.5 M NaCl/5 mM Na3EDTA at 60'C for 16 hr. Gel fragments were removed by centrifugation (14,000 x g, 5 min) and the solution containing the oligonucleotide was loaded onto a C18 Sep-Pak cartridge (Waters) equilibrated in water. The bound oligonucleotide was washed with 20 ml of water and eluted with 3 ml of 25 mM triethylammonium acetate, pH 7.3, in 50% methanol. The purified oligonucleotide was lyophilized, washed with 100% ethanol, and resuspended in water. Each globin gene was constructed from 14 separate oligonucleotides ranging in length from 50 to 85 Abbreviation: IPTG, isopropyl 8-D-thiogalactopyranoside. *To whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. nucleotides. Only the two oligonucleotides corresponding to the 5' ends of each construct were not phosphorylated. Each gene was assembled, separately, in a single annealing and ligation reaction (7) . The fragment corresponding to the a-globin gene was cloned into bacteriophage vector M13mp-19 (8) that had been digested with Xma I and Pst I. The ,8-globin fragment was cloned into Pst I-and HindIII-digested M13mpl9. Nucleotide sequencing (9) of M13 transfectants was used to identify isolates containing genes with the correct sequence. The a-and 8-globin genes were then cloned sequentially into the plasmid pKK223-3 (Pharmacia) as EcoRI-Pst I and Pst I-HindIII fragments, respectively. The resulting plasmid (pDLIII-13e, Fig. 1 ) contains the two globin genes cotranscribed from the Piac promoter (10) . The translational initiation site for the a-globin cistron is that described by Schoner et al. (11) . The translational coupler used to link the a-globin and f-globin cistrons is shown in Fig. 1 . In addition to pDLIII-13e, plasmids designed to express either a-globin or 8-globin alone were also constructed from pKK223-3. These constructs (pDLII-86c and pJRIV-50a, respectively) use the same translational initiation site as in the respective genes in pDLIII-13e. E. coli JM109 was transformed (12) with the plasmids described above.
Purification of Hb. E. coli JM109(pDLIII-13e) was grown (10,000 x g, 10 min, 4°C) and resuspended in 40 mM sodium phosphate (pH 7.0) (3 ml/g of cell paste). Aprotinin [200 kallikrein inhibitory units (KIU)/ml], DNase I (20 mg/ml), and lysozyme (2 mg/g of cell paste) were added, and the cells were broken by four passes through a Dynomill cell disrupter (Glen Mills, Maywood, NJ). The suspension was centrifuged (14,000 x g, 45 min, 4°C) and the supernatant, containing recombinant Hb, was bound to a dextran sulfate-Sephadex (Pharmacia) column (5 x 7 cm, equilibrated in 40 mM sodium phosphate, pH 7.0). After loading, the column was washed with 10 mM sodium phosphate (pH 7.0) containing aprotinin (100 KIU/ml). Hb was eluted with 20 mM Tris HCI (pH 7.5) containing aprotinin (100 KIU/ml). The eluted Hb was concentrated with a Centricon-30 concentrator (Amicon) and loaded onto a 20-ml Mono Q FPLC column (Pharmacia). Hb was eluted with a 240-ml linear gradient of 0-0.16 M NaCl in 20 mM Tris HCl (pH 8.0). The major Hb peak was eluted at 40 mM NaCl. Fractions containing Hb were concentrated and the buffer was exchanged by diafiltration (Centricon-30). Hb in 10 mM sodium phosphate (pH 7.0) was loaded onto a 20-ml Mono S FPLC column (Pharmacia) equilibrated in the same buffer. Hb was eluted with a 200-ml linear gradient from 10 mM sodium phosphate at pH 7.0 to 0.16 M NaCI/10 mM sodium phosphate at pH 9.0.
Human Hb AO was purified from red blood cells by modifications of existing procedures (13) and the methods described above.
Separation of a-and g3-Globin Chains and Protein Sequencing. The a-and 3-globin chains from recombinant Hb were separated by reverse-phase HPLC on a Vydac C4 column (25 x 0.46 cm) with a gradient of 30-60% acetonitrile containing 0.1% trifluoroacetic acid. Protein sequence data were obtained from nonreduced, HPLC-purified samples by using an Applied Biosystems model 477A protein sequencer, followed by HPLC analysis of phenylthiocarbamoyl-derivatized amino acids (14) .
Analytical Methods. Protein concentration was determined by the bicinchoninic acid (BCA) protein assay (Pierce) with crystallized human Hb or egg white lysozyme as standard. The concentration of Hb in solution was determined using published extinction coefficients (13) . Heme content was estimated by integrating the peaks obtained from reversephase HPLC (see above) and comparison to known standards. Methemoglobin was determined by the method of Drabkin and Austin (15) .
The method of Laemmli (16) was used for polyacrylamide gel electrophoresis of proteins. Electrophoresis of nucleic acids was as described by Maniatis et al. (12) .
Oxygen Affinity Measurements. Oxygen equilibrium curves were measured in a Hemox analyzer (TCS Medical Products, Southampton, PA) at 25.0 + 0.1°C in 50 mM Hepes/0.1 M NaCl. Oxygen equilibrium curves were measured by N2 deoxygenation of oxyhemoglobin previously equilibrated with water-saturated 02 or air. Both the absorbance and the oxygen pressure were sampled by a programmable-gain 12-bit analog-to-digital converter (Labmaster PGH; Scientific Solutions Solon, OH) under computer control. The oxygen equilibrium curve was subjected to a low-pass digital filter. P50 values (partial pressure of 02 required for 50% saturation) and Hill coefficients (nmax) were calculated from the digitally filtered data by using software developed in our laboratory. The Hill coefficients were determined as the maximum slope of the function d log[ y/(1 -y)]/d log p (17) .
RESULTS
Coexpression of a-and 13-Globin Genes in E. coli. To achieve coexpression of stoichiometric amounts of a-and f3-globin, we designed a Hb operon. Synthetic a-and P-globin genes were assembled and cloned into the pKK223-3 expresProc. Natl. Acad. Sci. USA 87 (1990) v sion vector to create pDLIII-13e (Fig. 1A) . The operon, under the regulation of the Plac promoter (10), consisted of two pairs of cistrons, one each for a-and /8-globin. Cotranslational coupling sequences were used to increase ribosomal loading (Fig. 1B) . Each globin gene contained separate ribosome binding and translational initiation and termination sites. The a-and ,8-globin genes were synthesized using an E. coli codon bias to enhance expression (18) and with restriction endonuclease sites regularly placed to aid in the construction of altered forms of Hb. Analogous expression vectors carrying only the a-and f3-globin gene were constructed to allow comparison of coexpression with expression of the genes separately.
E. coli JM109 cultures transformed with these plasmids were grown to midlogarithmic phase and globin synthesis was induced by the addition of IPTG. Cells were harvested 4 hr after the addition of inducer and analyzed by SDS/PAGE (Fig. 2) . Cells bearing pDLIII-13e accumulated two polypeptides, in approximately equal amounts, that comigrated with a-or 8-globin. Cells bearing the 3-globin expression vector produced, as expected, a polypeptide that comigrated with authentic f3-globin. E. coli JM109 transformed with the a-globin expression vector, however, did not produce detectable quantities of a-globin as assayed by staining with Coomassie brilliant blue. We were able to detect trace quantities of a-globin when immunological staining procedures were used (data not shown).
Separation of E. coli lysates into soluble and insoluble fractions (Fig. 3 ) demonstrated that coexpressed a-and ,B-globin were found predominantly in the soluble fraction. In cells producing only f3-globin, however, the protein was found primarily in the insoluble fraction (D.L.L., unpublished data). Based on the absence of pigmented material, it appears that heme was not incorporated into B3-globin under these conditions. These results suggest that a synergistic action between a-and ,B-globin may affect correct folding of (Fig. 6 Upper) was reduced by -50%. A possible explanation is that the proton-mediated effect on oxygen affinity was partially disrupted by the additional aminoterminal residue on a-and/or /-globin. The effect of pH on the cooperativity of recombinant Hb was not, however, significantly affected by the additional residue (Fig. 6 Lower). Inositol hexakisphosphate binding lowered the affinity for oxygen, demonstrating that the phosphate binding site in the 13 cleft was functional ( Table 1 ). The presence of the additional methionine on recombinant Hb, however, appeared to decrease the response to inositol hexaphosphate relative to Hb AO.
DISCUSSION
In many respects, E. coli is an excellent choice of organism in which to attempt to express heteromultimeric proteins. The organization of most E. coli genes into operons suggests an obvious way to attempt production of proteins that consist of several different polypeptides-namely, the construction of synthetic operons in which the expression of the subunits is co-regulated. Several heteromultimeric proteins have been produced in E. coli, including the hexadecameric ribulosebisphosphate carboxylase (19) , immunoglobulin Fv fragments (20) , and chimeric Fab fragments (21) . Our Hb operon was designed to overcome difficulties in producing stoichiometric amounts of the two globin chains. This was apparently successful. An equivalent level of mRNA coding sequences alone is unlikely to provide the basis for this success.
The plasmid designed for coexpression of a-and f3-globin produces an mRNA molecule with potentially different secondary structure than mRNA coding only for a-or ,3-globin.
These differences could result in variations in mRNA stability or translation efficiency. However, the striking difference in polypeptide levels seen when a-and P-globin genes were expressed alone suggests that posttranscriptional effects involving a/f3-globin interactions may be critical to protein folding and stability. It is clear that coexpression of a-and /3-globin influences the intracellular distribution of /3-globin. The ability to produce functional recombinant Hb de novo in the system described in this paper facilitates the production of Hb mutants (S.J.H., D.L.L., and G.L.S., unpublished data). Specific amino acid substitutions incorporated into recombinant Hb modeling naturally occurring mutants (29) or rationally designed Hb variants (30) could be used to modulate oxygen affinity. Other specific mutations could be used to stabilize Hb to dissociation and oxidation. Such genetically engineered Hb could provide advantages over mammalian Hb for use in a red-cell substitute.
